• Kewaunee Scientific shareholder meeting deck highlighted FY2026 revenue of $282 million, EBITDA of $22.4 million, pre-tax earnings of $13.7 million.
• Net earnings were $9.6 million; long-term debt fell about $20 million; debt-to-equity improved to 0.61-to-1.
• Lab Products Group segment revenue rose to $214.9 million from $179.4 million; International revenue was $67.1 million from $61.1 million.
• Backlog ended at $165.9 million, up from $214.6 million; Lab Products Group backlog was $118.8 million; International backlog was $47.1 million.
• Deck outlined no proposals for shareholder votes; strategy emphasized international expansion, a new Spain entity, systems and SOX 404(b) readiness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kewaunee Scientific Corporation published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.